EN
抗体药类似物
Research Grade Imdevimab
All
TD-VK565056_1.jpg
TD-VK565056_2.jpg
TD-VK565056_3.jpg
  • CatalogTD-VK565056
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsREGN-10987,REGN10987,CAS:2415933-40-1
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Imdevimab


Catalog No. TD-VK565056
Species reactivity SARS-CoV-2 (2019-nCoV)
Applications Research Grade Biosimilar
Host species Human
Isotype IgG1, lambda
Expression system Mammalian Cells
Clonality Monoclonal
Target Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P0DTC2
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names REGN-10987,REGN10987,CAS:2415933-40-1
Background Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases.
Note For research use only. Not for use in clinical or therapeutic applications.

 

TD-VK565056_1.jpg
SEC-HPLC
 
SEC-HPLC detection for Research Grade Imdevimab.
TD-VK565056_2.jpg
Bioactivity
 
Detects Recombinant SARS-CoV-2 Spike protein receptor binding domain (Cat No.: TD-VK565021) in indirect ELISA.
TD-VK565056_3.jpg
SDS-PAGE
 
SDS-PAGE for Research Grade Imdevimab.